Johnson & Johnson (J&J) has accepted private investment firm Platinum Equity鈥檚 binding offer to acquire its subsidiary LifeScan for around $2.1bn.
The decision follows consultation with associated works councils and trade unions. This offer was originally proposed in March this year and is subject to customary closing conditions and regulatory clearances.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
LifeScan offers blood glucose monitoring systems under the brand OneTouch to allow diabetes management. Its products are designed for simple and accurate testing at hospitals as well as home.
Used by nearly 20 million patients across more than 90 countries, OneTouch products include glucose metres and accessories, insulin pumps, testing strips, lancets, point-of-care systems for testing and integrated digital solutions.
The company reported net revenue of around $1.5bn last year.
Platinum Equity plans to leverage its financial resources and operating expertise to support LifeScan鈥檚 goal to enhance the quality of life of diabetes patients.
US Tariffs are shifting - will you react or anticipate?
Don鈥檛 let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataAfter the completion of the transaction, which is scheduled to complete by the end of this year, LifeScan will operate as a global standalone business and provide a platform for continued investment to boost growth and innovation.
A statement from J&J read: 鈥淭he Johnson & Johnson Family of Companies will continue to serve those impacted by diabetes through innovative products, services and solutions from its 吃瓜黑料网, Pharmaceuticals and Consumer businesses.
鈥淭hese include important leadership and innovation in areas such as bariatric surgery and through medicines such as INVOKANA (canagliflozin) and INVOKAMET (canagliflozin/metformin HCl).鈥�
